## Edgar Filing: Scopa James Paul - Form 4

Scopa James Form 4	Paul											
January 15, 2	009											
FORM	4								PPROVAL			
		SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number:	3235-0287				
Check this if no long subject to Section 16 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	er <b>STATE</b> 5. Filed p <sup>18</sup> nue. Section 1	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							January 31, 2005 Estimated average burden hours per response 0.5			
(Print or Type R	esponses)											
1. Name and Address of Reporting Person <u>*</u> Scopa James Paul			2. Issuer Name <b>and</b> Ticker or Trading Symbol PEPLIN INC [PLI]				ıg	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First)	(Middle)	3. Date of Earliest Transaction			(Check all applicable)						
C/O MPM A MANAGEM BLVD., SUI	IENT, 601 GA	TEWAY	(Month/D 01/13/20	-				X Director Officer (give below)	e titleOtho below)	6 Owner er (specify		
	(Street)	. , ,			endment, Date Original nth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
SOUTH SAN	N O, CA 94080							Person		F		
(City)	(State)	(Zip)	Table	e I - Non-D	erivative	Securi	ties Acc	quired, Disposed o	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date any (Month/Day/Year)		on Date, if	Date, if Transaction Code		4 and (A)	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)				
Common Stock	01/13/2009			Р	6,911 (1)	А	\$ 7.03	2,872,257	Ι	See Footnote $(2)$		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Scopa James Paul - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Inst
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships						
		Director	10% Owner	Officer	Other			
Scopa James Paul C/O MPM ASSET MANAGEMENT 601 GATEWAY BLVD., SUITE 350 SOUTH SAN FRANCISCO, CA 94080		Х	Х					
Signatures								
/s/ James Paul Scopa	01/15/2009							
**0. 6	D.							

Signature of Reporting Person Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents shares of Common Stock underlingy CHESS Depository Interests ("CDIs") acquired by the reporting person. The CDIs are economically equivalent to shares of Common Stock of the Issuer on a 1-for-20 basis. The Common Stock equivalent of CDIs were purchased as follows: 6,478 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 249 by MPM BioVentures IV GmbH & Co. Beteiligungs

(1) KG ("BV IV KG") and 184 by MPM Asset Management Investors BV4 LLC ("AM BV4"). Excludes fractional shares that result from the conversion of CDIs. MPM BioVentures IV GP LLC and MPM BioVentures IV LLC are the direct and indirect general partners of BV IV QP, BV IV KG and AM BV4. The reporting person is a member of the general partner of BV IV QP, BV IV KG and a member of AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Shares of Common Stock, which include shares underlying CDIs are held as follows: 2,691,999 by BV IV QP, 103,710 by BV IV KG, (2) 76,548 by AM BV4. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest

therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.